Krystal Biotech receives regulatory approval to expand to Japan
By Jake Dabkowski
Dystrophic Epidermolysis Bullosa Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Thera
Recessive Dystrophic Epidermolysis Bullosa Pipeline Insight
The Bull Case For Krystal Biotech (KRYS) Could Change Following First Genetic Medicine Approval in Japan
Japan's MHLW Highlights Four Key Themes in Pharmaceuticals and Medical Devices Act Timeline Amendment | Insights
By Katherine Wang
Japan health ministry panel backs Eli Lilly dementia drug donanemab
By Rocky Swift & Andrew Heavens